{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:42:05Z","timestamp":1789605725120,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-54290-2","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T18:23:19Z","timestamp":1731522199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The IL-1\u03b2 inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Juan Jose","family":"Rodriguez-Sevilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6051-4378","authenticated-orcid":false,"given":"Vera","family":"Adema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-1613","authenticated-orcid":false,"given":"Kelly S.","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-0787","authenticated-orcid":false,"given":"Feiyang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4533-5176","authenticated-orcid":false,"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1192-9336","authenticated-orcid":false,"given":"Xuelin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joby","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Bodden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6583-8910","authenticated-orcid":false,"given":"Simona","family":"Colla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"54290_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1158\/2643-3230.BCD-22-0176","volume":"4","author":"JC Balandr\u00e1n","year":"2023","unstructured":"Balandr\u00e1n, J. C., Lasry, A. & Aifantis, I. The role of inflammation in the initiation and progression of myeloid neoplasms. Blood Cancer Discov. 4, 254\u2013266 (2023).","journal-title":"Blood Cancer Discov."},{"key":"54290_CR2","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/leu.2015.69","volume":"29","author":"I Ganan-Gomez","year":"2015","unstructured":"Ganan-Gomez, I. et al. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia 29, 1458\u20131469 (2015).","journal-title":"Leukemia"},{"key":"54290_CR3","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.stem.2022.05.006","volume":"29","author":"MA Florez","year":"2022","unstructured":"Florez, M. A. et al. Clonal hematopoiesis: mutation-specific adaptation to environmental change. Cell Stem Cell 29, 882\u2013904 (2022).","journal-title":"Cell Stem Cell"},{"key":"54290_CR4","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.stem.2021.03.002","volume":"28","author":"D Hormaechea-Agulla","year":"2021","unstructured":"Hormaechea-Agulla, D. et al. Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFN\u03b3 signaling. Cell Stem Cell 28, 1428\u20131442.e1426 (2021).","journal-title":"Cell Stem Cell"},{"key":"54290_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/cmi.2016.25","volume":"14","author":"KD Mayer-Barber","year":"2017","unstructured":"Mayer-Barber, K. D. & Yan, B. Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses. Cell Mol. Immunol. 14, 22\u201335 (2017).","journal-title":"Cell Mol. Immunol."},{"key":"54290_CR6","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/cdd.2015.176","volume":"23","author":"F Mart\u00edn-S\u00e1nchez","year":"2016","unstructured":"Mart\u00edn-S\u00e1nchez, F. et al. Inflammasome-dependent IL-1\u03b2 release depends upon membrane permeabilisation. Cell Death Differ. 23, 1219\u20131231 (2016).","journal-title":"Cell Death Differ."},{"key":"54290_CR7","first-page":"cm1","volume":"3","author":"A Weber","year":"2010","unstructured":"Weber, A., Wasiliew, P. & Kracht, M. Interleukin-1 (IL-1) pathway. Sci. Signal. 3, cm1 (2010).","journal-title":"Sci. Signal."},{"key":"54290_CR8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ncb3346","volume":"18","author":"EM Pietras","year":"2016","unstructured":"Pietras, E. M. et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nat. Cell Biol. 18, 607\u2013618 (2016).","journal-title":"Nat. Cell Biol."},{"key":"54290_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41556-022-01053-0","volume":"25","author":"CA Mitchell","year":"2023","unstructured":"Mitchell, C. A. et al. Stromal niche inflammation mediated by IL-1 signalling is a targetable driver of haematopoietic ageing. Nat. Cell Biol. 25, 30\u201341 (2023).","journal-title":"Nat. Cell Biol."},{"key":"54290_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","volume":"7","author":"EC Svensson","year":"2022","unstructured":"Svensson, E. C. et al. TET2-Driven clonal hematopoiesis and response to Canakinumab: an exploratory analysis of the CANTOS Randomized Clinical Trial. JAMA Cardiol. 7, 521\u2013528 (2022).","journal-title":"JAMA Cardiol."},{"key":"54290_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43697-y","volume":"14","author":"J McClatchy","year":"2023","unstructured":"McClatchy, J. et al. Clonal hematopoiesis related TET2 loss-of-function impedes IL1\u03b2-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells. Nat. Commun. 14, 8102 (2023).","journal-title":"Nat. Commun."},{"key":"54290_CR12","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1038\/s41375-022-01665-3","volume":"36","author":"SS Burns","year":"2022","unstructured":"Burns, S. S. et al. Il-1r1 drives leukemogenesis induced by Tet2 loss. Leukemia 36, 2531\u20132534 (2022).","journal-title":"Leukemia"},{"key":"54290_CR13","doi-asserted-by":"publisher","first-page":"7471","DOI":"10.1182\/bloodadvances.2023011578","volume":"7","author":"J Woo","year":"2023","unstructured":"Woo, J. et al. Effects of IL-1\u03b2 inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial. Blood Adv. 7, 7471\u20137484 (2023).","journal-title":"Blood Adv."},{"key":"54290_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.immuni.2020.11.005","volume":"54","author":"DA Mogilenko","year":"2021","unstructured":"Mogilenko, D. A. et al. Comprehensive profiling of an aging immune system reveals clonal GZMK(+) CD8(+) T cells as conserved hallmark of inflammaging. Immunity 54, 99\u2013115.e112 (2021).","journal-title":"Immunity"},{"key":"54290_CR15","doi-asserted-by":"publisher","first-page":"eabo0686","DOI":"10.1126\/scitranslmed.abo0686","volume":"14","author":"AH Jonsson","year":"2022","unstructured":"Jonsson, A. H. et al. Granzyme K(+) CD8 T cells form a core population in inflamed human tissue. Sci. Transl. Med. 14, eabo0686 (2022).","journal-title":"Sci. Transl. Med."},{"key":"54290_CR16","first-page":"27","volume":"4","author":"A Lasry","year":"2023","unstructured":"Lasry, A. et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat. Cancer 4, 27\u201342 (2023).","journal-title":"Nat. Cancer"},{"key":"54290_CR17","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","volume":"15","author":"M Efremova","year":"2020","unstructured":"Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat. Protoc. 15, 1484\u20131506 (2020).","journal-title":"Nat. Protoc."},{"key":"54290_CR18","doi-asserted-by":"publisher","unstructured":"Hindy, G. et al. Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis. J. Clin. Investig. 132. https:\/\/doi.org\/10.1172\/jci158788 (2022).","DOI":"10.1172\/jci158788"},{"key":"54290_CR19","doi-asserted-by":"publisher","unstructured":"Rawat, K. et al. CCL5-producing migratory dendritic cells guide CCR5+ monocytes into the draining lymph nodes. J. Exp. Med. 220. https:\/\/doi.org\/10.1084\/jem.20222129 (2023).","DOI":"10.1084\/jem.20222129"},{"key":"54290_CR20","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga, A. J., Chow, M. T. & Luster, A. D. Chemokines and the immune response to cancer. Immunity 54, 859\u2013874 (2021).","journal-title":"Immunity"},{"key":"54290_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.4049\/jimmunol.2001310","volume":"207","author":"R Luque-Martin","year":"2021","unstructured":"Luque-Martin, R. et al. IFN-\u03b3 drives human monocyte differentiation into highly proinflammatory macrophages that resemble a phenotype relevant to Psoriasis. J. Immunol. 207, 555\u2013568 (2021).","journal-title":"J. Immunol."},{"key":"54290_CR22","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.4049\/jimmunol.1103324","volume":"188","author":"N Wimmer","year":"2012","unstructured":"Wimmer, N. et al. Lymphotoxin \u03b2 receptor activation on macrophages induces cross-tolerance to TLR4 and TLR9 ligands. J. Immunol. 188, 3426\u20133433 (2012).","journal-title":"J. Immunol."},{"key":"54290_CR23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with Canakinumab for Atherosclerotic Disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"54290_CR24","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","volume":"390","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833\u20131842 (2017).","journal-title":"Lancet"},{"key":"54290_CR25","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg, P. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079\u20132088 (1997).","journal-title":"Blood"},{"key":"54290_CR26","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg, P. L. et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120, 2454\u20132465 (2012).","journal-title":"Blood"},{"key":"54290_CR27","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard, E. et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 1, EVIDoa2200008 (2022).","journal-title":"NEJM Evid."},{"key":"54290_CR28","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2021012652","volume":"139","author":"CA Clough","year":"2022","unstructured":"Clough, C. A. et al. Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome. Blood 139, 2038\u20132049 (2022).","journal-title":"Blood"},{"key":"54290_CR29","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/s41375-024-02249-z","volume":"38","author":"S Winter","year":"2024","unstructured":"Winter, S. et al. Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DR(low\/neg) monocytes in lower-risk myelodysplastic neoplasms. Leukemia 38, 1427\u20131431 (2024).","journal-title":"Leukemia"},{"key":"54290_CR30","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/s41375-023-01949-2","volume":"37","author":"M Schneider","year":"2023","unstructured":"Schneider, M. et al. Activation of distinct inflammatory pathways in subgroups of LR-MDS. Leukemia 37, 1709\u20131718 (2023).","journal-title":"Leukemia"},{"key":"54290_CR31","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1182\/blood-2016-07-730556","volume":"128","author":"AA Basiorka","year":"2016","unstructured":"Basiorka, A. A. et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood 128, 2960\u20132975 (2016).","journal-title":"Blood"},{"key":"54290_CR32","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.3324\/haematol.2016.158857","volume":"102","author":"T Cluzeau","year":"2017","unstructured":"Cluzeau, T. et al. Pro-inflammatory proteins S100A9 and tumor necrosis factor-\u03b1 suppress erythropoietin elaboration in myelodysplastic syndromes. Haematologica 102, 2015\u20132020 (2017).","journal-title":"Haematologica"},{"key":"54290_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1586\/14737159.2016.1142374","volume":"16","author":"R Kanagal-Shamanna","year":"2016","unstructured":"Kanagal-Shamanna, R. et al. Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory. Expert Rev. Mol. Diagn. 16, 461\u2013472 (2016).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"54290_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46424-3","volume":"15","author":"JJ Rodriguez-Sevilla","year":"2024","unstructured":"Rodriguez-Sevilla, J. J. et al. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes. Nat. Commun. 15, 2428 (2024).","journal-title":"Nat. Commun."},{"key":"54290_CR35","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e1821 (2019).","journal-title":"Cell"},{"key":"54290_CR36","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/ni.2615","volume":"14","author":"E Laurenti","year":"2013","unstructured":"Laurenti, E. et al. The transcriptional architecture of early human hematopoiesis identifies multilevel control of lymphoid commitment. Nat. Immunol. 14, 756\u2013763 (2013).","journal-title":"Nat. Immunol."},{"key":"54290_CR37","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.stem.2015.01.017","volume":"16","author":"E Laurenti","year":"2015","unstructured":"Laurenti, E. et al. CDK6 levels regulate quiescence exit in human hematopoietic stem cells. cell stem cell 16, 302\u2013313 (2015).","journal-title":"cell stem cell"},{"key":"54290_CR38","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/ncb3493","volume":"19","author":"L Velten","year":"2017","unstructured":"Velten, L. et al. Human haematopoietic stem cell lineage commitment is a continuous process. Nat. Cell Biol. 19, 271\u2013281 (2017).","journal-title":"Nat. Cell Biol."},{"key":"54290_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06442-4","volume":"9","author":"S Belluschi","year":"2018","unstructured":"Belluschi, S. et al. Myelo-lymphoid lineage restriction occurs in the human haematopoietic stem cell compartment before lymphoid-primed multipotent progenitors. Nat. Commun. 9, 4100 (2018).","journal-title":"Nat. Commun."},{"key":"54290_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).","journal-title":"Nat. Commun."},{"key":"54290_CR41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson, B. D. et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108, 419\u2013425 (2006).","journal-title":"Blood"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54290-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54290-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54290-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T19:05:30Z","timestamp":1731524730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54290-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54290"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54290-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.G-M. declares research funding from Astex Pharmaceuticals, Novartis, Abbvie, BMS, Genentech, Aprea Therapeutics, Curis, Gilead Sciences; consulting fees from Astex Pharmaceuticals, Acceleron Pharma, and BMS; and payments or honoraria from Astex Pharmaceuticals, Acceleron Pharma, Abbvie, Novartis, Gilead Sciences, Curis, Genentech, and BMS. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9840"}}